- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- February 2025
- 182 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- April 2024
- 30 Pages
Global
From €3231EUR$3,550USD£2,770GBP
- Report
- November 2023
- 262 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- March 2021
- 132 Pages
Global
From €13647EUR$14,995USD£11,699GBP
Vemlidy is a prescription medication used to treat chronic hepatitis B virus (HBV) infection in adults. It is a nucleotide analog, which works by blocking the virus from replicating and spreading in the body. Vemlidy is the first and only once-daily oral medication approved for the treatment of chronic HBV infection in adults. It is also approved for use in combination with other antiviral medications. Vemlidy is a part of the larger market of drugs used to treat liver and kidney disorders. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, and kidney failure. They can also be used to prevent or slow the progression of certain diseases.
The market for drugs used to treat liver and kidney disorders is highly competitive, with many companies offering a variety of treatments. Some of the major players in this market include Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb. Other companies include Novartis, Pfizer, and AstraZeneca. Show Less Read more
